Crossmark

Loncastuximab tesirine: an effective therapy for relapsed or refractory diffuse large B-cell lymphoma

Crossref DOI link: https://doi.org/10.1007/s00228-021-03253-3

Published Online: 2022-01-21

Published Print: 2022-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Xu, Bo https://orcid.org/0000-0003-0594-9103
License Information

Text and Data Mining valid from 2022-01-21

Version of Record valid from 2022-01-21
More Information

Article History

Received: 23 May 2021

Accepted: 15 November 2021

First Online: 21 January 2022

Declarations

:

: Not applicable.

: Bo Xu declare that he has no conflicts of interest.